Glasdegib in combination with low-dose cytarabine, for the treatment of newly diagnosed de novo or secondary acute myeloid leukaemia (AML) in adult patients who are not candidates for standard induction chemotherapy
Federation of Social Insurances (DVSV)
Record ID 32018001148
English
Authors' objectives:
This is the pharmaceutical Joint Assessment PTJA12 – on glasdegib for the treatment of acute myeloid leukaemia (AML). In June 2020, the European Commission granted marketing authorisation for Daurismo® (glasdegib), in combination with low-dose cytarabine, for the treatment of newly diagnosed de novo or secondary AML in adult patients who are not candidates for standard induction chemotherapy. This Joint Assessment aims to compare the clinical effectiveness and safety of glasdegib, in combination with low-dose cytarabine, in the target patient population with relevant comparators (azacitidine, decitabine, low-dose cytarabine, and best supportive care) according to the national requirements of EUnetHTA partners.
Details
Project Status:
Completed
URL for project:
https://eunethta.eu/ptja12/
Year Published:
2020
URL for published report:
https://eunethta.eu/ptja12/
Requestor:
HTA agencies
English language abstract:
An English language summary is available
Publication Type:
Rapid Review
MeSH Terms
- Leukemia
- Leukemia, Myeloid
- Leukemia, Myeloid, Acute
- Adult
- Antineoplastic Combined Chemotherapy Protocols
- Benzimidazoles
- Cytarabine
- Phenylurea Compounds
Contact
Organisation Name:
European Network for Health Technology Assessment
Contact Email:
eunethta@zinl.nl
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.